Research Analysts Set Expectations for NBIX Q1 Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Equities researchers at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Neurocrine Biosciences in a report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman anticipates that the company will post earnings of $0.91 per share for the quarter. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $3.92 per share.

Several other research firms have also recently weighed in on NBIX. Barclays raised their price target on Neurocrine Biosciences from $160.00 to $165.00 and gave the company an “overweight” rating in a report on Monday, December 23rd. BMO Capital Markets reduced their price target on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research report on Thursday, October 17th. Royal Bank of Canada lowered their price objective on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a research report on Friday, October 4th. Piper Sandler restated an “overweight” rating and issued a $160.00 target price on shares of Neurocrine Biosciences in a report on Monday, December 23rd. Finally, Raymond James reaffirmed an “outperform” rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a report on Thursday, October 10th. Five investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $166.10.

Neurocrine Biosciences Trading Up 1.7 %

Shares of NBIX stock opened at $153.29 on Friday. The stock has a market capitalization of $15.52 billion, a price-to-earnings ratio of 41.10 and a beta of 0.33. Neurocrine Biosciences has a 12-month low of $110.95 and a 12-month high of $157.98. The stock’s 50-day moving average price is $135.88 and its 200-day moving average price is $131.44.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of institutional investors have recently added to or reduced their stakes in the stock. Golden State Wealth Management LLC acquired a new position in shares of Neurocrine Biosciences during the fourth quarter worth $25,000. Brooklyn Investment Group increased its position in Neurocrine Biosciences by 99.1% during the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock valued at $32,000 after buying an additional 115 shares in the last quarter. Blue Trust Inc. raised its stake in Neurocrine Biosciences by 171.9% in the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after buying an additional 220 shares during the last quarter. R Squared Ltd purchased a new stake in shares of Neurocrine Biosciences during the fourth quarter worth about $61,000. Finally, UMB Bank n.a. grew its stake in shares of Neurocrine Biosciences by 211.6% during the fourth quarter. UMB Bank n.a. now owns 455 shares of the company’s stock worth $62,000 after acquiring an additional 309 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Insider Buying and Selling at Neurocrine Biosciences

In related news, insider Ingrid Delaet sold 272 shares of the business’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $138.10, for a total value of $37,563.20. Following the completion of the transaction, the insider now owns 2,507 shares of the company’s stock, valued at $346,216.70. The trade was a 9.79 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Jude Onyia sold 2,331 shares of the stock in a transaction on Friday, November 29th. The shares were sold at an average price of $126.29, for a total value of $294,381.99. Following the sale, the insider now directly owns 15,449 shares in the company, valued at $1,951,054.21. This trade represents a 13.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 214,799 shares of company stock valued at $31,513,583 in the last ninety days. Corporate insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.